Genus plc (LON:GNS)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.44B -7.1% |
| Revenue (ttm) | 658.10M -2.2% |
| Net Income | 285.30M +1,378.2% |
| EPS | 4.25 +1,370.9% |
| Shares Out | 66.92M |
| PE Ratio | 5.06 |
| Forward PE | 20.56 |
| Dividend | 0.35 (1.64%) |
| Ex-Dividend Date | Nov 12, 2026 |
| Volume | 289,329 |
| Open | 2,098.00 |
| Previous Close | 2,142.00 |
| Day's Range | 2,098.00 - 2,196.00 |
| 52-Week Range | 1,943.00 - 3,220.00 |
| Beta | 0.90 |
| Analysts | Strong Buy |
| Price Target | 3,030.83 (+40.97%) |
| Earnings Date | Sep 10, 2026 |
About Genus
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom. [Read more]
Financial Performance
In fiscal year 2026, Genus's revenue was 658.10 million, a decrease of -2.18% compared to the previous year's 672.80 million. Earnings were 285.30 million, an increase of 1378.24%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for GNS stock is "Strong Buy." The 12-month stock price target is 3,031p, which is an increase of 40.97% from the latest price.
News
Florida Court Denies Dismissal Motions in Genius Group (GNS) $1 Billion Lawsuit
Florida Court Denies Dismissal Motions in Genius Group (GNS) $1 Billion Lawsuit
Genius Group (GNS) Reports 140% Revenue Growth in H1 2026 Amid Restructuring
Genius Group (GNS) Reports 140% Revenue Growth in H1 2026 Amid Restructuring
Genus H2 Earnings Call Highlights
Genus LON: GNS reported higher adjusted profit and cash generation for FY 2026, supported by growth in its porcine genetics business, efficiency gains in bovine genetics and contributions from joint v...
Genus Earnings Call Transcript: H2 2026
Adjusted profit before tax and EPS rose 35% year-over-year, with strong free cash flow and a materially strengthened balance sheet. Strategic progress included regulatory approvals for PRP, a major JV in China, and a GBP 60 million share buyback. Moderate profit growth is expected in FY 2027.
Genus Annual report: H2 2026
Genus has published its H2 2026 annual report on September 10, 2026.
Genus Slides: H2 2026
Genus has posted slides in relation to its H2 2026 quarterly earnings report, which was published on September 10, 2026.
GNS Looks 157.1% Overvalued on GF Value™
GNS Looks 157.1% Overvalued on GF Value™
Genus upgraded to Buy from Hold at Kepler Cheuvreux
Kepler Cheuvreux upgraded Genus (GENSF) to Buy from Hold with a 2,800 GBp price target
Genus Earnings release: Trading update
Genus released its earnings on July 14, 2026, summarizing the period's financial results.
Genus initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Genus (GENSF) with an Overweight rating and 3,200 GBp price target The firm expects consistent growth in the company’s core porcine and bovine genetics businesses. Publi...
Genus initiated with a Neutral at BNP Paribas
BNP Paribas initiated coverage of Genus (GENSF) with a Neutral rating and 2,750 GBp price target
Genus Power Surpasses 26 Million Smart Meter Deployment Worldwide, Reinforcing Leadership in End-to-End Advanced Metering Solutions
JAIPUR, India, March 2, 2026 /PRNewswire/ -- Genus Power (NSE: GENUSPOWER) (BSE: 530343), India's leading end-to-end energy measurement and advanced metering solutions provider, has crossed a signific...
Genus Earnings Call Transcript: H1 2026
Record first half profit driven by strong PIC growth, especially in China, and ABS margin improvement from VAP initiatives. Regulatory progress on PRP and the China JV formation position the group for long-term growth. FY26 adjusted PBT is expected to grow significantly.
Genus Quarterly report: H1 2026
Genus has published its H1 2026 quarterly earnings report on February 26, 2026.
Genus Slides: H1 2026
Genus has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 26, 2026.
Genus price target raised to 3,350 GBp from 3,250 GBp at Berenberg
Berenberg analyst Robert Chantry raised the firm’s price target on Genus (GENSF) to 3,350 GBp from 3,250 GBp and keeps a Buy rating on the shares.
UK animal genetics firm Genus surges on annual profit forecast upgrade
British animal genetics company Genus expects to report full-year adjusted pretax profit "moderately above" the upper end of current market expectations, sending its shares as much as 15.3% higher on ...
Genus Earnings release: Trading update
Genus released its earnings on January 16, 2026, summarizing the period's financial results.
Genus Slides: 44th Annual J.P. Morgan Healthcare Conference Presentation
Genus has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
British animal genetics firm Genus surges on strong annual profit growth
Shares of British animal genetics firm Genus shot up nearly 29% on Thursday, after it reported a 38% surge in annual adjusted pretax profit, on a constant currency basis.
Genus Earnings Call Transcript: H2 2025
Strong financial and strategic progress was achieved, including robust profit growth, record free cash flow, and the accelerated PIC China JV. Market conditions are stable overall, with some headwinds in China, and significant growth in adjusted profit before tax is expected for FY26.
Genus Annual report: H2 2025
Genus has published its H2 2025 annual report on September 4, 2025.
Genus Annual report: H2 2025
Genus has published its H2 2025 annual report on September 4, 2025.
Genus Slides: H2 2025
Genus has posted slides in relation to its H2 2025 quarterly earnings report, which was published on September 4, 2025.
Genus Earnings release: Trading Update
Genus released its earnings on July 15, 2025, summarizing the period's financial results.